← Back to Screener
AngioDynamics, Inc. (ANGO)
Price$10.79
Favorite Metrics
Price vs S&P 500 (26W)-9.94%
Price vs S&P 500 (4W)-7.39%
Market Capitalization$449.55M
All Metrics
Book Value / Share (Quarterly)$4.16
P/TBV (Annual)3.46x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.56%
Cash Flow / Share (Quarterly)$0.04
Price vs S&P 500 (YTD)-19.90%
Gross Margin (TTM)54.30%
Net Profit Margin (TTM)-10.00%
EPS (TTM)$-0.76
10-Day Avg Trading Volume0.52M
EPS Excl Extra (TTM)$-0.76
Revenue Growth (5Y)2.06%
EPS (Annual)$-0.83
ROI (Annual)-17.97%
Gross Margin (Annual)53.92%
Net Profit Margin (5Y Avg)-21.39%
Cash / Share (Quarterly)$0.91
Revenue Growth QoQ (YoY)8.91%
ROA (Last FY)-12.13%
Revenue Growth TTM (YoY)10.73%
EBITD / Share (TTM)$-0.50
ROE (5Y Avg)-27.10%
Operating Margin (TTM)-11.32%
Cash Flow / Share (Annual)$-0.36
P/B Ratio2.59x
P/B Ratio (Quarterly)2.70x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.33x
Net Interest Coverage (TTM)-19.15x
ROA (TTM)-11.67%
EV / EBITDA (TTM)51.95x
EPS Incl Extra (Annual)$-0.83
Current Ratio (Annual)2.21x
Quick Ratio (Quarterly)1.26x
3-Month Avg Trading Volume0.54M
52-Week Price Return13.34%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.59
P/S Ratio (Annual)1.54x
Asset Turnover (Annual)1.04x
52-Week High$13.99
Operating Margin (5Y Avg)-22.65%
EPS Excl Extra (Annual)$-0.83
CapEx CAGR (5Y)-10.07%
Tangible BV CAGR (5Y)-15.08%
26-Week Price Return-3.05%
Quick Ratio (Annual)1.30x
13-Week Price Return-2.00%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)2.35x
Enterprise Value$417.64
Revenue / Share Growth (5Y)0.59%
Asset Turnover (TTM)1.17x
Book Value / Share Growth (5Y)-17.86%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.20x
Pretax Margin (Annual)-11.63%
Cash / Share (Annual)$1.36
3-Month Return Std Dev49.82%
Gross Margin (5Y Avg)52.50%
Net Income / Employee (TTM)$-0
ROE (Last FY)-18.58%
Net Interest Coverage (Annual)-129.23x
EPS Basic Excl Extra (Annual)$-0.83
P/FCF (TTM)20.18x
Receivables Turnover (TTM)7.05x
EV / Free Cash Flow (TTM)277.87x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-0.76
Receivables Turnover (Annual)6.76x
ROI (TTM)-17.06%
P/S Ratio (TTM)1.43x
Pretax Margin (5Y Avg)-22.52%
Revenue / Share (Annual)$7.16
Tangible BV / Share (Annual)$2.78
Price vs S&P 500 (52W)-21.29%
Year-to-Date Return-15.97%
5-Day Price Return3.06%
EPS Normalized (Annual)$-0.83
ROA (5Y Avg)-18.08%
Net Profit Margin (Annual)-11.62%
Month-to-Date Return-5.10%
Cash Flow / Share (TTM)$0.92
EBITD / Share (Annual)$-0.60
Operating Margin (Annual)-13.66%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)101.07x
ROI (5Y Avg)-26.53%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.76
P/TBV (Quarterly)4.34x
P/B Ratio (Annual)2.15x
Inventory Turnover (TTM)2.36x
Pretax Margin (TTM)-10.00%
Book Value / Share (Annual)$4.46
Price vs S&P 500 (13W)-4.38%
Beta0.35x
P/FCF (Annual)23.79x
Revenue / Share (TTM)$7.54
ROE (TTM)-17.65%
52-Week Low$8.36
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ANGOAngioDynamics, Inc. | 1.43x | 2.06% | 54.30% | -11.32% | $10.79 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
AngioDynamics Inc develops and manufactures specialized medical devices for treating peripheral vascular disease and supporting oncology and surgical procedures. The company generates the majority of its revenue from sales to U.S. healthcare providers.